Complete reversal of ischemic wall motion abnormalities by combined use of gene therapy with transmyocardial laser revascularization

U. Sayeed-Shah, M. J. Mann, J. Martin, S. Grachev, S. Reimold, R. Laurence, V. Dzau, L. H. Cohn, T. Rosengart, C. R. Bridges, R. C. Robbins

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Introduction: Transmyocardial laser revascularization is believed to induce an angiogenic response within ischemic myocardium. We evaluated transgene expression in the setting of transmyocardial laser revascularization and hypothesized that intramyocardial injection of plasmid DNA encoding the gene for vascular endothelial growth factor could enhance the revascularization achieved by transmyocardial laser revascularization, resulting in improved cardiac function. Methods: Ten Yorkshire pigs had carbon dioxide-transmyocardial laser revascularization or acupuncture sites with injections of an expression plasmid encoding the gene for β- galactosidase with or without HVJ-liposomes. Three days after transduction, transgene expression was determined by enzyme-linked immunosorbent assay. Six weeks after placement of a constrictor on the left circumflex artery, 29 pigs were randomized to ischemic controls (u = 5), transmyocardial laser revascularization (n = 4), transmyocardial laser revascularization with expression plasmid β-galactosidase injections (n = 5), expression plasmid- vascular endothelial growth factor injections (n = 4), or transmyocardial laser revascularization with expression plasmid-vascular endothelial growth factor (n = 5) and harvested 6 weeks after therapy. Six transmyocardial laser revascularization pigs had either expression plasmid β-galactosidase or expression plasmid-vascular endothelial growth factor injections and were harvested at 2 weeks. Normal pigs (n = 5) were included for comparison. Left ventricular free wall motion was assessed by a cardiologist in a blinded manner. Results: Transgene expression did not vary significantly with or without HVJ-liposomes in transfected transmyocardial laser revascularization myocardium. However, expression was detected in 56 of 60 (93%) transmyocardial laser revascularization-transfected sites, but in only 10 of 20 (50%) non-transmyocardial laser revascularization sites (P < .001). All (5 of 5 hearts) of the transmyocardial laser revascularization-vascular endothelial growth factor treated hearts displayed no evidence of wall motion abnormalities. Only these hearts had a statistically significantly different rate of wall motion abnormality compared with ischemic controls (P = .004). Conclusion: Transfection efficiency was improved with the use of transmyocardial laser revascularization. Wall motion abnormalities were completely reversed within 6 weeks after transmyocardial laser revascularization with the direct injection of an expression plasmid encoding vascular endothelial growth factor.

Original languageEnglish (US)
Pages (from-to)763-769
Number of pages7
JournalJournal of Thoracic and Cardiovascular Surgery
Volume116
Issue number5
DOIs
StatePublished - 1998

Fingerprint

Transmyocardial Laser Revascularization
Genetic Therapy
Plasmids
Vascular Endothelial Growth Factor A
Galactosidases
Injections
Swine
Transgenes
Liposomes
Myocardium
Gas Lasers
Acupuncture

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Complete reversal of ischemic wall motion abnormalities by combined use of gene therapy with transmyocardial laser revascularization. / Sayeed-Shah, U.; Mann, M. J.; Martin, J.; Grachev, S.; Reimold, S.; Laurence, R.; Dzau, V.; Cohn, L. H.; Rosengart, T.; Bridges, C. R.; Robbins, R. C.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 116, No. 5, 1998, p. 763-769.

Research output: Contribution to journalArticle

Sayeed-Shah, U, Mann, MJ, Martin, J, Grachev, S, Reimold, S, Laurence, R, Dzau, V, Cohn, LH, Rosengart, T, Bridges, CR & Robbins, RC 1998, 'Complete reversal of ischemic wall motion abnormalities by combined use of gene therapy with transmyocardial laser revascularization', Journal of Thoracic and Cardiovascular Surgery, vol. 116, no. 5, pp. 763-769. https://doi.org/10.1016/S0022-5223(98)00440-1
Sayeed-Shah, U. ; Mann, M. J. ; Martin, J. ; Grachev, S. ; Reimold, S. ; Laurence, R. ; Dzau, V. ; Cohn, L. H. ; Rosengart, T. ; Bridges, C. R. ; Robbins, R. C. / Complete reversal of ischemic wall motion abnormalities by combined use of gene therapy with transmyocardial laser revascularization. In: Journal of Thoracic and Cardiovascular Surgery. 1998 ; Vol. 116, No. 5. pp. 763-769.
@article{f774a8365f184a0cb9590f468625cce6,
title = "Complete reversal of ischemic wall motion abnormalities by combined use of gene therapy with transmyocardial laser revascularization",
abstract = "Introduction: Transmyocardial laser revascularization is believed to induce an angiogenic response within ischemic myocardium. We evaluated transgene expression in the setting of transmyocardial laser revascularization and hypothesized that intramyocardial injection of plasmid DNA encoding the gene for vascular endothelial growth factor could enhance the revascularization achieved by transmyocardial laser revascularization, resulting in improved cardiac function. Methods: Ten Yorkshire pigs had carbon dioxide-transmyocardial laser revascularization or acupuncture sites with injections of an expression plasmid encoding the gene for β- galactosidase with or without HVJ-liposomes. Three days after transduction, transgene expression was determined by enzyme-linked immunosorbent assay. Six weeks after placement of a constrictor on the left circumflex artery, 29 pigs were randomized to ischemic controls (u = 5), transmyocardial laser revascularization (n = 4), transmyocardial laser revascularization with expression plasmid β-galactosidase injections (n = 5), expression plasmid- vascular endothelial growth factor injections (n = 4), or transmyocardial laser revascularization with expression plasmid-vascular endothelial growth factor (n = 5) and harvested 6 weeks after therapy. Six transmyocardial laser revascularization pigs had either expression plasmid β-galactosidase or expression plasmid-vascular endothelial growth factor injections and were harvested at 2 weeks. Normal pigs (n = 5) were included for comparison. Left ventricular free wall motion was assessed by a cardiologist in a blinded manner. Results: Transgene expression did not vary significantly with or without HVJ-liposomes in transfected transmyocardial laser revascularization myocardium. However, expression was detected in 56 of 60 (93{\%}) transmyocardial laser revascularization-transfected sites, but in only 10 of 20 (50{\%}) non-transmyocardial laser revascularization sites (P < .001). All (5 of 5 hearts) of the transmyocardial laser revascularization-vascular endothelial growth factor treated hearts displayed no evidence of wall motion abnormalities. Only these hearts had a statistically significantly different rate of wall motion abnormality compared with ischemic controls (P = .004). Conclusion: Transfection efficiency was improved with the use of transmyocardial laser revascularization. Wall motion abnormalities were completely reversed within 6 weeks after transmyocardial laser revascularization with the direct injection of an expression plasmid encoding vascular endothelial growth factor.",
author = "U. Sayeed-Shah and Mann, {M. J.} and J. Martin and S. Grachev and S. Reimold and R. Laurence and V. Dzau and Cohn, {L. H.} and T. Rosengart and Bridges, {C. R.} and Robbins, {R. C.}",
year = "1998",
doi = "10.1016/S0022-5223(98)00440-1",
language = "English (US)",
volume = "116",
pages = "763--769",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Complete reversal of ischemic wall motion abnormalities by combined use of gene therapy with transmyocardial laser revascularization

AU - Sayeed-Shah, U.

AU - Mann, M. J.

AU - Martin, J.

AU - Grachev, S.

AU - Reimold, S.

AU - Laurence, R.

AU - Dzau, V.

AU - Cohn, L. H.

AU - Rosengart, T.

AU - Bridges, C. R.

AU - Robbins, R. C.

PY - 1998

Y1 - 1998

N2 - Introduction: Transmyocardial laser revascularization is believed to induce an angiogenic response within ischemic myocardium. We evaluated transgene expression in the setting of transmyocardial laser revascularization and hypothesized that intramyocardial injection of plasmid DNA encoding the gene for vascular endothelial growth factor could enhance the revascularization achieved by transmyocardial laser revascularization, resulting in improved cardiac function. Methods: Ten Yorkshire pigs had carbon dioxide-transmyocardial laser revascularization or acupuncture sites with injections of an expression plasmid encoding the gene for β- galactosidase with or without HVJ-liposomes. Three days after transduction, transgene expression was determined by enzyme-linked immunosorbent assay. Six weeks after placement of a constrictor on the left circumflex artery, 29 pigs were randomized to ischemic controls (u = 5), transmyocardial laser revascularization (n = 4), transmyocardial laser revascularization with expression plasmid β-galactosidase injections (n = 5), expression plasmid- vascular endothelial growth factor injections (n = 4), or transmyocardial laser revascularization with expression plasmid-vascular endothelial growth factor (n = 5) and harvested 6 weeks after therapy. Six transmyocardial laser revascularization pigs had either expression plasmid β-galactosidase or expression plasmid-vascular endothelial growth factor injections and were harvested at 2 weeks. Normal pigs (n = 5) were included for comparison. Left ventricular free wall motion was assessed by a cardiologist in a blinded manner. Results: Transgene expression did not vary significantly with or without HVJ-liposomes in transfected transmyocardial laser revascularization myocardium. However, expression was detected in 56 of 60 (93%) transmyocardial laser revascularization-transfected sites, but in only 10 of 20 (50%) non-transmyocardial laser revascularization sites (P < .001). All (5 of 5 hearts) of the transmyocardial laser revascularization-vascular endothelial growth factor treated hearts displayed no evidence of wall motion abnormalities. Only these hearts had a statistically significantly different rate of wall motion abnormality compared with ischemic controls (P = .004). Conclusion: Transfection efficiency was improved with the use of transmyocardial laser revascularization. Wall motion abnormalities were completely reversed within 6 weeks after transmyocardial laser revascularization with the direct injection of an expression plasmid encoding vascular endothelial growth factor.

AB - Introduction: Transmyocardial laser revascularization is believed to induce an angiogenic response within ischemic myocardium. We evaluated transgene expression in the setting of transmyocardial laser revascularization and hypothesized that intramyocardial injection of plasmid DNA encoding the gene for vascular endothelial growth factor could enhance the revascularization achieved by transmyocardial laser revascularization, resulting in improved cardiac function. Methods: Ten Yorkshire pigs had carbon dioxide-transmyocardial laser revascularization or acupuncture sites with injections of an expression plasmid encoding the gene for β- galactosidase with or without HVJ-liposomes. Three days after transduction, transgene expression was determined by enzyme-linked immunosorbent assay. Six weeks after placement of a constrictor on the left circumflex artery, 29 pigs were randomized to ischemic controls (u = 5), transmyocardial laser revascularization (n = 4), transmyocardial laser revascularization with expression plasmid β-galactosidase injections (n = 5), expression plasmid- vascular endothelial growth factor injections (n = 4), or transmyocardial laser revascularization with expression plasmid-vascular endothelial growth factor (n = 5) and harvested 6 weeks after therapy. Six transmyocardial laser revascularization pigs had either expression plasmid β-galactosidase or expression plasmid-vascular endothelial growth factor injections and were harvested at 2 weeks. Normal pigs (n = 5) were included for comparison. Left ventricular free wall motion was assessed by a cardiologist in a blinded manner. Results: Transgene expression did not vary significantly with or without HVJ-liposomes in transfected transmyocardial laser revascularization myocardium. However, expression was detected in 56 of 60 (93%) transmyocardial laser revascularization-transfected sites, but in only 10 of 20 (50%) non-transmyocardial laser revascularization sites (P < .001). All (5 of 5 hearts) of the transmyocardial laser revascularization-vascular endothelial growth factor treated hearts displayed no evidence of wall motion abnormalities. Only these hearts had a statistically significantly different rate of wall motion abnormality compared with ischemic controls (P = .004). Conclusion: Transfection efficiency was improved with the use of transmyocardial laser revascularization. Wall motion abnormalities were completely reversed within 6 weeks after transmyocardial laser revascularization with the direct injection of an expression plasmid encoding vascular endothelial growth factor.

UR - http://www.scopus.com/inward/record.url?scp=18344408673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18344408673&partnerID=8YFLogxK

U2 - 10.1016/S0022-5223(98)00440-1

DO - 10.1016/S0022-5223(98)00440-1

M3 - Article

C2 - 9806383

AN - SCOPUS:18344408673

VL - 116

SP - 763

EP - 769

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 5

ER -